Old Drugs as New Treatments for Neurodegenerative Diseases
Neurodegenerative diseases are increasing in number, given that the general global population is becoming older. They manifest themselves through mechanisms that are not fully understood, in many cases, and impair memory, cognition and movement. Currently, no neurodegenerative disease is curable, an...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1424-8247/11/2/44 |
| _version_ | 1811206456632934400 |
|---|---|
| author | Fernando Durães Madalena Pinto Emília Sousa |
| author_facet | Fernando Durães Madalena Pinto Emília Sousa |
| author_sort | Fernando Durães |
| collection | DOAJ |
| description | Neurodegenerative diseases are increasing in number, given that the general global population is becoming older. They manifest themselves through mechanisms that are not fully understood, in many cases, and impair memory, cognition and movement. Currently, no neurodegenerative disease is curable, and the treatments available only manage the symptoms or halt the progression of the disease. Therefore, there is an urgent need for new treatments for this kind of disease, since the World Health Organization has predicted that neurodegenerative diseases affecting motor function will become the second-most prevalent cause of death in the next 20 years. New therapies can come from three main sources: synthesis, natural products, and existing drugs. This last source is known as drug repurposing, which is the most advantageous, since the drug’s pharmacokinetic and pharmacodynamic profiles are already established, and the investment put into this strategy is not as significant as for the classic development of new drugs. There have been several studies on the potential of old drugs for the most relevant neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis. |
| first_indexed | 2024-04-12T03:48:56Z |
| format | Article |
| id | doaj.art-c2a296160a6c4b3d968de2128ad5b0d4 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-04-12T03:48:56Z |
| publishDate | 2018-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-c2a296160a6c4b3d968de2128ad5b0d42022-12-22T03:49:03ZengMDPI AGPharmaceuticals1424-82472018-05-011124410.3390/ph11020044ph11020044Old Drugs as New Treatments for Neurodegenerative DiseasesFernando Durães0Madalena Pinto1Emília Sousa2Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, PortugalLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, PortugalLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, PortugalNeurodegenerative diseases are increasing in number, given that the general global population is becoming older. They manifest themselves through mechanisms that are not fully understood, in many cases, and impair memory, cognition and movement. Currently, no neurodegenerative disease is curable, and the treatments available only manage the symptoms or halt the progression of the disease. Therefore, there is an urgent need for new treatments for this kind of disease, since the World Health Organization has predicted that neurodegenerative diseases affecting motor function will become the second-most prevalent cause of death in the next 20 years. New therapies can come from three main sources: synthesis, natural products, and existing drugs. This last source is known as drug repurposing, which is the most advantageous, since the drug’s pharmacokinetic and pharmacodynamic profiles are already established, and the investment put into this strategy is not as significant as for the classic development of new drugs. There have been several studies on the potential of old drugs for the most relevant neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.http://www.mdpi.com/1424-8247/11/2/44neurodegenerative diseasesdrug repurposingAlzheimer’s diseaseParkinson’s diseaseHuntington’s diseasemultiple sclerosisamyotrophic lateral sclerosis |
| spellingShingle | Fernando Durães Madalena Pinto Emília Sousa Old Drugs as New Treatments for Neurodegenerative Diseases Pharmaceuticals neurodegenerative diseases drug repurposing Alzheimer’s disease Parkinson’s disease Huntington’s disease multiple sclerosis amyotrophic lateral sclerosis |
| title | Old Drugs as New Treatments for Neurodegenerative Diseases |
| title_full | Old Drugs as New Treatments for Neurodegenerative Diseases |
| title_fullStr | Old Drugs as New Treatments for Neurodegenerative Diseases |
| title_full_unstemmed | Old Drugs as New Treatments for Neurodegenerative Diseases |
| title_short | Old Drugs as New Treatments for Neurodegenerative Diseases |
| title_sort | old drugs as new treatments for neurodegenerative diseases |
| topic | neurodegenerative diseases drug repurposing Alzheimer’s disease Parkinson’s disease Huntington’s disease multiple sclerosis amyotrophic lateral sclerosis |
| url | http://www.mdpi.com/1424-8247/11/2/44 |
| work_keys_str_mv | AT fernandoduraes olddrugsasnewtreatmentsforneurodegenerativediseases AT madalenapinto olddrugsasnewtreatmentsforneurodegenerativediseases AT emiliasousa olddrugsasnewtreatmentsforneurodegenerativediseases |